Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial

BACKGROUND: Chronic liver scarring from any cause leads to cirrhosis, portal hypertension, and a progressive decline in renal blood flow and renal function. Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially reversible form of acute kidney injury in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Snowdon, Victoria K., Lachlan, Neil J., Hoy, Anna M., Hadoke, Patrick W. F., Semple, Scott I., Patel, Dilip, Mungall, Will, Kendall, Timothy J., Thomson, Adrian, Lennen, Ross J., Jansen, Maurits A., Moran, Carmel M., Pellicoro, Antonella, Ramachandran, Prakash, Shaw, Isaac, Aucott, Rebecca L., Severin, Thomas, Saini, Rajnish, Pak, Judy, Yates, Denise, Dongre, Neelesh, Duffield, Jeremy S., Webb, David J., Iredale, John P., Hayes, Peter C., Fallowfield, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330452/
https://www.ncbi.nlm.nih.gov/pubmed/28245243
http://dx.doi.org/10.1371/journal.pmed.1002248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330452/
https://www.ncbi.nlm.nih.gov/pubmed/28245243
http://dx.doi.org/10.1371/journal.pmed.1002248

Ejemplares similares